Comparative Pharmacology
Head-to-head clinical analysis: INCRUSE ELLIPTA versus SPIRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCRUSE ELLIPTA versus SPIRIVA.
INCRUSE ELLIPTA vs SPIRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Umeclidinium is a long-acting muscarinic antagonist (LAMA). It competitively inhibits M3 muscarinic receptors in the airways, reducing acetylcholine-induced bronchoconstriction and mucus secretion.
Tiotropium is a long-acting muscarinic antagonist (LAMA) that blocks M3 receptors in the airways, inhibiting acetylcholine-induced bronchoconstriction and mucus secretion.
Inhalation: 1 inhalation (62.5 mcg umeclidinium) once daily.
18 mcg inhalation via HandiHaler once daily, or 2.5 mcg (2 puffs) via Respimat inhaler once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 11 hours (range 10–13 hours) after inhalation, supporting once-daily dosing.
Terminal elimination half-life is 27–46 hours (mean ~30 hours) after inhalation. The long half-life supports once-daily dosing due to sustained bronchodilation.
Umeclidinium is eliminated primarily by hepatic metabolism and biliary excretion; after oral administration, approximately 58% of the dose is excreted in feces (mostly as parent drug) and about 22% in urine. Renal excretion of unchanged drug is minimal (<1%).
Renal excretion accounts for approximately 60% (mainly as unchanged drug) following intravenous administration; biliary/fecal excretion accounts for about 30% (as non-absorbed drug after oral inhalation). Less than 20% is metabolized via ester hydrolysis (nonspecific esterases) to inactive metabolites.
Category C
Category C
Anticholinergic Bronchodilator
Anticholinergic Bronchodilator